As of June 21, 2025, Flexion Therapeutics Inc (FLXN) reports a Net Margin of -132.92%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Flexion Therapeutics Inc's Net Margin
Over recent years, Flexion Therapeutics Inc's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2020-12-31 | -132.92% |
| 2019-12-31 | -205.28% |
| 2018-12-31 | -753.38% |
| 2017-12-31 | -38188.90% |
This steady improvement highlights how Flexion Therapeutics Inc manages its overall profitability and cost control over time.
Comparing Flexion Therapeutics Inc's Net Margin to Peers
To better understand Flexion Therapeutics Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Flexion Therapeutics Inc (FLXN) | -132.92% |
| ADMA Biologics Inc (ADMA) | 46.35% |
| Catalyst Pharmaceuticals Inc (CPRX) | 33.33% |
| Regeneron Pharmaceuticals Inc (REGN) | 31.07% |
| MEI Pharma Inc (MEIP) | 27.23% |
| Amgen Inc (AMGN) | 12.24% |
Compared to its competitors, Flexion Therapeutics Inc's Net Margin is about average compared to peers, reflecting typical industry profitability.